About us
Nottingham Technology Ventures Ltd is a wholly owned subsidiary of the University of Nottingham. Its role is to advise the University of Nottingham on the formation of spin-out companies and the management of its spin-out company portfolio. It also advises on the management of investments from the Pathfinder Fund and the Nottingham Invention Fund.
Nottingham Technology Ventures is based in the Ingenuity Centre within the University of Nottingham Innovation Park (UNIP). The Nottingham Invention Fund is a £5m fund dedicated to investing in University spin-out companies to accelerate their development and growth.
The University of Nottingham currently has 22 spin-outs in the portfolio and has achieved significant exits from its previous portfolio, demonstrating significant success in the past three years.
Our board
Dr Andrew Naylor
Professor Dame Jessica Corner
Dr Susan Huxtable
Professor Andy Long
Margaret Monckton
Spin-out company formation and development is the remit of the University’s Intellectual Property (IP) and business formation advisors based in our IP Commercialisation Office.
While the specifics of any company development may be unique, there are a number of common elements and the IP office has developed standard mechanisms and support structures to help with this process.
NTV News
Locate Bio raises £2.25m for new spinal treatments
Locate Bio, who are developing new treatments for patients with serious spinal conditions, has completed a £2.25m funding round led by Mercia Asset Management to
University of Nottingham invests in startup developing next generation energy storage technology
The University of Nottingham has announced an investment into innovative energy storage company, Cheesecake Energy Ltd (CEL). The funding from the University comes with assistance
University of Nottingham generates £1.5m from the sale of Oncimmune shares
Spin-out company continues to develop world-leading expertise in early cancer detection The University has realised more than £1.5m from the sale of shares in Oncimmune